NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Oregon U-turns on Doubling Psilocybin License Fees
After weeks of organized resistance in the form of public comments, Oregon's health regulators have shelved a proposal that would have doubled what psilocybin businesses and facilitators pay for their state licenses. ...
Enveric Biosciences reported positive results from more than 70 IND-enabling ADMET assays for its non-hallucinogenic neuroplastogenic candidate EB-003.
The in vitro studies indicated favourable intestinal absorption, systemic exposure, metabolic stability across species including humans, and predictable elimination. EB-003 did not significantly affect major metabolic...
Helus Pharma said HLP003’s APPROACH Phase 3 topline data remain on track for Q4 2026, while its HLP004 Phase 2 monotherapy study for GAD is expected to start in Q1 2027.
Helus Pharma reported continued development of HLP003 for adjunctive treatment of major depressive disorder and HLP004 for monotherapy treatment of generalised anxiety disorder. Enrollment is continuing in the EMBRACE...
Horizons 2026: New Medicines for an Old System
As pharmaceutical companies and mainstream medicine increasingly embrace psychedelic therapies, attendees at the nineteenth Horizons conference examined barriers to access and the broader paradox of how psychedelics c...
LSD does more than desynchronize the brain—it changes brain rhythms and signal complexity
First synthesized in a laboratory in 1938 by the Swiss chemist Albert Hofmann, lysergic acid diethylamide, better known by its acronym LSD, is one of the most potent and most extensively studied psychedelics.
Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments
The growing interest in psychedelic medicine has offered a potentially different path forward. Researchers have increasingly turned their attention to compounds capable of influencing neuroplasticity, the brain’s abil...
Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
At The Psychedelic Healthcare Forum that we co-hosted last Thursday in New York, our Editor Josh Hardman sat down with Matt Zorn, Deputy General Counsel at the U.S. Department of Health and Human Services, for a wide-...
Did Ancient Buddhists Drink Visionary Mushroom Elixirs?
A Buddhist lama thinks amrita, a medieval sacramental elixir, contained psychedelic mushrooms. [...] Read More...
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
CAMBRIDGE, Mass., October 21, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address…
From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics
Documentary filmmaker Jordan Kronick joins Joe to discuss Peaking: Psychedelics and the Pursuit of Happiness, a new psychedelic documentary that takes cameras into the dosing room across six psychedelics. They cover h...
Elevated Healing Center has opened Colorado’s first state-licensed psilocybin healing centre in the Pikes Peak region, offering supervised sessions for adults aged 21 and over.
Elevated Healing Center in Manitou Springs provides screening, preparation, a guided psilocybin session and follow-up discussions. Fees are about $550 for the centre and $400 to $900 for a facilitator, with scholarshi...
Psyence BioMed says both milestones of its US$2.60 million backstop investment in PsyLabs have been met, including regulatory documentation and a US manufacturing agreement for pharmaceutical-grade ibogaine.
PsyLabs completed an ibogaine regulatory readiness package to support future regulatory interactions for pharmaceutical-grade ibogaine HCl. Its subsidiary, Texas Ibogaine Research Corporation, also executed a US cGMP ...
A UCSF study found lower inflammatory markers in 12 people with Parkinson’s disease after two psilocybin sessions, with changes lasting about a month.
Researchers measured blood inflammatory markers and a mitochondrial stress marker in 12 people with Parkinson’s disease before and after two psilocybin sessions. Inflammatory markers were lower for about a month, whil...
PsyRx reported that ibogaine combined with citalopram produced a statistically significant improvement on one anxiety-related measure in a study of 105 mice.
The preclinical study divided 105 mice into seven groups to assess ibogaine, citalopram and their combination in a depression and anxiety model. Some numerical improvements were seen with low-dose ibogaine plus citalo...
What Psychedelics Have Taught Me About Paying Attention as a Father
Kevin Cranford of MAPS writes about how a few psychedelic experiences taught him to slow down, stay calm and meet his two sons where they are. That covers a five-minute walk that takes half an hour, and a tantrum that...